MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- UNICHEM LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Unichem Lab Quarterly Results (UNCHM)
Here are the latest quarterly results of Unichem Lab. For more details, see the Unichem Lab financial fact sheet and Unichem Lab share price and chart. For a sector overview, read our pharmaceuticals sector report.
Unichem Lab Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,591 | 2,051 | 2,014 | 2,459 | 2,448 | 2,771 | 2,325 | 2,251 | |
| Other income | Rs m | 67 | 454 | 193 | 326 | 276 | 226 | 280 | 290 | |
| Turnover | Rs m | 1,658 | 2,505 | 2,207 | 2,785 | 2,723 | 2,996 | 2,605 | 2,541 | |
| Expenses | Rs m | 2,142 | 2,311 | 2,401 | 2,441 | 2,644 | 2,819 | 2,506 | 2,609 | |
| Gross profit | Rs m | -551 | -260 | -387 | 18 | -196 | -48 | -181 | -358 | |
| Depreciation | Rs m | 115 | 128 | 123 | 148 | 168 | 177 | 169 | 179 | |
| Interest | Rs m | 9 | 5 | 0 | 1 | 1 | 4 | 0 | 2 | |
| Profit before tax | Rs m | -608 | 62 | -317 | 195 | -90 | -4 | -70 | -249 | |
| Tax | Rs m | -29 | 34 | -110 | 18 | -153 | -41 | -75 | 0 | |
| Profit after tax | Rs m | -580 | 28 | -207 | 177 | 63 | 37 | 5 | -249 | |
| Gross profit margin | % | -34.6 | -12.7 | -19.2 | 0.7 | -8.0 | -1.7 | -7.8 | -15.9 | |
| Effective tax rate | % | 4.7 | 54.6 | 34.8 | 9.4 | 170.1 | 1,066.8 | 106.6 | 0.0 | |
| Net profit margin | % | -36.4 | 1.4 | -10.3 | 7.2 | 2.6 | 1.3 | 0.2 | -11.0 | |
| Diluted EPS | Rs | -6.4 | 0.3 | -2.3 | 1.9 | 0.7 | 0.4 | 0.1 | -2.7 | |
| Diluted EPS (TTM) | Rs | 2.3 | -0.9 | -3.3 | -6.4 | 0.7 | 0.8 | 3.1 | -1.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Unichem Lab 1QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: GLENMARK PHARMA FDC LTD. ASTRAZENECA PHARMA LUPIN ELDER PHARMA
Compare UNICHEM LAB With: GLENMARK PHARMA FDC LTD. ASTRAZENECA PHARMA LUPIN ELDER PHARMA
Compare UNICHEM LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Buzz on the Street: A Look at Stocks, Sectors and the Economy(Podcast)
The stock markets in India remained rangebound this week. Economic data releases and third quarter results announcements were the focus of the week.
Views on news
UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)
Jul 30, 2019 | Updated on Jul 30, 2019For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)
Jul 4, 2019 | Updated on Jul 4, 2019Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.
UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)
May 29, 2019 | Updated on May 29, 2019For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Bet on These Smallcap Stocks for Success in 2020 (Profit Hunter)
Jan 14, 2020The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)
Jan 17, 2020Don't fall for the safe stocks narrative going around in the stock market these days.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
More|
| |
OUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
UNICHEM LAB SHARE PRICE
Jan 24, 2020 (Close)
TRACK UNICHEM LAB
- Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON UNICHEM LAB
UNICHEM LAB - GLENMARK PHARMA COMPARISON
COMPARE UNICHEM LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.